A Wuhan-based affiliate of China National Pharmaceutical Group (Sinopharm) said the start of operations at a new factory will raise the annual production capacity of its COVID-19 vaccine to at least 1 billion doses.
The Wuhan Institute of Biological Products made the announcement in a statement released late on Monday through social media. It did not specify when it will operate the factory at full capacity.
Still, the announcement marks a step toward state-backed Sinopharm’s annual capacity target of 3 billion doses for its COVID-19 vaccines.
The Beijing Institute of Biological Products, another Sinopharm affiliate whose shot gained emergency-use approval from the World Health Organization, has a factory with annual capacity of 1 billion doses and is also building a new facility.
China has approved four COVID-19 vaccines from domestic makers Sinopharm, Sinovac Biotech Ltd and CanSino Biologics Inc for general public use, and three other vaccines for emergency use.
Sinovac, whose COVID-19 vaccine capacity is 2 billion doses per year, on Tuesday said it has supplied over 600 million doses at home and abroad as of the end of May.
Sinopharm vaccine: Chinese scientists publish world’s first report on clinical trialsTwo inactivated vaccines developed by Chinese pharmaceutical giant Sinopharm have been proven safe and effective against COVID-19 in Phase III human ... Coronavirus
GAVI in talks with China’s Sinopharm, others to expand COVAX reachThe GAVI Vaccine Alliance is in talks with COVID-19 vaccine manufacturers including China’s state-owned Sinopharm to expand the COVAX pipeline and ... Coronavirus
WHO gives emergency approval to Sinopharm, first Chinese COVID-19 vaccineThe World Health Organization announced on Friday it had approved a COVID-19 vaccine from China’s state-owned drugmaker Sinopharm for emergency ... Coronavirus